FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551596549> ?p ?o ?g. }

• W2551596549 endingPage "86647" @default.
• W2551596549 startingPage "86630" @default.
• W2551596549 abstract "// Mu-xing Li 1 , Hong Zhao 1 , Xin-yu Bi 1 , Zhi-yu Li 1 , Xue-song Yao 2 , Huai Li 2 , Zhen Huang 1 , Yue Han 2 , Jian-guo Zhou 1 , Jian-jun Zhao 1 , Ye-fan Zhang 1 , Dong-bin Zhao 1 , Jian-qiang Cai 1 1 Department of Abdominal Surgical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing 100021, P. R. China 2 Department of Interventional Therapies, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing 100021, P. R. China Correspondence to: Jian-qiang Cai, email: caijianqiang@cicams.ac.cn Hong Zhao, email: zhaohong9@sina.com Keywords: LDH, hepatocellular carcinoma, sorafenib, prognosis, HBV endemic area Received: April 07, 2016      Accepted: October 31, 2016      Published: November 17, 2016 ABSTRACT Purpose: Lactate dehydrogenase (LDH), which was an indirect marker of hypoxia, was a potentially prognostic factor in several malignancies. There is a lack of evidence about the prognostic value of serum LDH level in patients with hepatocellular carcinoma (HCC) receiving sorafenib treatment from hepatitis B virus endemic areas. Materials and Methods: A total of 119 HBV-related HCC patients treated by sorafenib from a Chinese center were included into the study. They were categorized into 2 groups according to the cut-off value of pre-treatment LDH, which was determined by the time dependent receiver operating characteristics (ROC) curve for the overall survival. The prognostic value of LDH was evaluated. The relationships between LDH and other clinicopathological factors were also assessed. Results: The cut-off value was 221 U/L. With a median follow up of 15 (range, 3-73) months, 91 patients reached the endpoint. Multivariate analysis proved that pre-treatment serum LDH level was an independent prognostic factor for both overall survival (OS) and progression-free survival (PFS). For patients whose pre-treatment LDH ≥ 221 U/L, increased LDH value after 3 months of sorafenib treatment predicted inferior OS and PFS. And patients with elevated pre-treatment LDH level predisposed to be featured with lower serum albumin, presence of macroscopic vascular invasion, advanced Child-Pugh class, advanced T category, higher AFP, and higher serum total bilirubin. Conclusions: Serum LDH level was a potentially prognostic factor in HCC patients treated by sorafenib in HBV endemic area. More relevant studies with reasonable study design are needed to further strengthen its prognostic value." @default.
• W2551596549 created "2016-11-30" @default.
• W2551596549 creator A5001023087 @default.
• W2551596549 creator A5010714615 @default.
• W2551596549 creator A5020454516 @default.
• W2551596549 creator A5024914167 @default.
• W2551596549 creator A5026749521 @default.
• W2551596549 creator A5031190682 @default.
• W2551596549 creator A5031998757 @default.
• W2551596549 creator A5062616621 @default.
• W2551596549 creator A5066958689 @default.
• W2551596549 creator A5067373934 @default.
• W2551596549 creator A5074411641 @default.
• W2551596549 creator A5074947237 @default.
• W2551596549 creator A5088178516 @default.
• W2551596549 date "2016-11-17" @default.
• W2551596549 modified "2023-09-27" @default.
• W2551596549 title "Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area" @default.
• W2551596549 cites W1574675143 @default.
• W2551596549 cites W1863396492 @default.
• W2551596549 cites W1964423256 @default.
• W2551596549 cites W1969378376 @default.
• W2551596549 cites W1971837077 @default.
• W2551596549 cites W1976048849 @default.
• W2551596549 cites W1982154889 @default.
• W2551596549 cites W1994193851 @default.
• W2551596549 cites W2016278725 @default.
• W2551596549 cites W2029131085 @default.
• W2551596549 cites W2031771562 @default.
• W2551596549 cites W2036953241 @default.
• W2551596549 cites W2072451938 @default.
• W2551596549 cites W2091068407 @default.
• W2551596549 cites W2093724516 @default.
• W2551596549 cites W2109202667 @default.
• W2551596549 cites W2125158357 @default.
• W2551596549 cites W2139248078 @default.
• W2551596549 cites W2147172608 @default.
• W2551596549 cites W2149988506 @default.
• W2551596549 cites W2151196497 @default.
• W2551596549 cites W2153793701 @default.
• W2551596549 cites W2163403599 @default.
• W2551596549 cites W2170552969 @default.
• W2551596549 cites W2190344224 @default.
• W2551596549 cites W2191906182 @default.
• W2551596549 cites W2223801424 @default.
• W2551596549 cites W2234453634 @default.
• W2551596549 cites W2272984102 @default.
• W2551596549 cites W2281848173 @default.
• W2551596549 cites W2292250576 @default.
• W2551596549 cites W2300749713 @default.
• W2551596549 cites W2339744455 @default.
• W2551596549 cites W2403567273 @default.
• W2551596549 doi "https://doi.org/10.18632/oncotarget.13428" @default.
• W2551596549 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5349941" @default.
• W2551596549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27880930" @default.
• W2551596549 hasPublicationYear "2016" @default.
• W2551596549 type Work @default.
• W2551596549 sameAs 2551596549 @default.
• W2551596549 citedByCount "7" @default.
• W2551596549 countsByYear W25515965492018 @default.
• W2551596549 countsByYear W25515965492019 @default.
• W2551596549 countsByYear W25515965492020 @default.
• W2551596549 countsByYear W25515965492021 @default.
• W2551596549 countsByYear W25515965492023 @default.
• W2551596549 crossrefType "journal-article" @default.
• W2551596549 hasAuthorship W2551596549A5001023087 @default.
• W2551596549 hasAuthorship W2551596549A5010714615 @default.
• W2551596549 hasAuthorship W2551596549A5020454516 @default.
• W2551596549 hasAuthorship W2551596549A5024914167 @default.
• W2551596549 hasAuthorship W2551596549A5026749521 @default.
• W2551596549 hasAuthorship W2551596549A5031190682 @default.
• W2551596549 hasAuthorship W2551596549A5031998757 @default.
• W2551596549 hasAuthorship W2551596549A5062616621 @default.
• W2551596549 hasAuthorship W2551596549A5066958689 @default.
• W2551596549 hasAuthorship W2551596549A5067373934 @default.
• W2551596549 hasAuthorship W2551596549A5074411641 @default.
• W2551596549 hasAuthorship W2551596549A5074947237 @default.
• W2551596549 hasAuthorship W2551596549A5088178516 @default.
• W2551596549 hasBestOaLocation W25515965491 @default.
• W2551596549 hasConcept C121608353 @default.
• W2551596549 hasConcept C126322002 @default.
• W2551596549 hasConcept C143998085 @default.
• W2551596549 hasConcept C2776231280 @default.
• W2551596549 hasConcept C2778019345 @default.
• W2551596549 hasConcept C2778695046 @default.
• W2551596549 hasConcept C556039675 @default.
• W2551596549 hasConcept C71924100 @default.
• W2551596549 hasConcept C90924648 @default.
• W2551596549 hasConceptScore W2551596549C121608353 @default.
• W2551596549 hasConceptScore W2551596549C126322002 @default.
• W2551596549 hasConceptScore W2551596549C143998085 @default.
• W2551596549 hasConceptScore W2551596549C2776231280 @default.
• W2551596549 hasConceptScore W2551596549C2778019345 @default.
• W2551596549 hasConceptScore W2551596549C2778695046 @default.
• W2551596549 hasConceptScore W2551596549C556039675 @default.
• W2551596549 hasConceptScore W2551596549C71924100 @default.
• W2551596549 hasConceptScore W2551596549C90924648 @default.
• W2551596549 hasIssue "52" @default.

• next